- Home
- INDB vs CELC Comparison
INDB vs CELC Comparison
Compare INDB & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDB
- CELC
- Stock Information
- Founded
- INDB 1907
- CELC 2011
- Country
- INDB United States
- CELC United States
- Employees
- INDB N/A
- CELC N/A
- Industry
- INDB Major Banks
- CELC Medical Specialities
- Sector
- INDB Finance
- CELC Health Care
- Exchange
- INDB Nasdaq
- CELC Nasdaq
- Market Cap
- INDB 3.5B
- CELC 2.8B
- IPO Year
- INDB N/A
- CELC 2017
- Fundamental
- Price
- INDB $68.02
- CELC $76.24
- Analyst Decision
- INDB Buy
- CELC Strong Buy
- Analyst Count
- INDB 4
- CELC 5
- Target Price
- INDB $74.00
- CELC $69.40
- AVG Volume (30 Days)
- INDB 298.5K
- CELC 1.6M
- Earning Date
- INDB 10-16-2025
- CELC 11-13-2025
- Dividend Yield
- INDB 3.46%
- CELC N/A
- EPS Growth
- INDB N/A
- CELC N/A
- EPS
- INDB 4.05
- CELC N/A
- Revenue
- INDB $712,223,000.00
- CELC N/A
- Revenue This Year
- INDB $33.63
- CELC N/A
- Revenue Next Year
- INDB $20.70
- CELC N/A
- P/E Ratio
- INDB $16.87
- CELC N/A
- Revenue Growth
- INDB 8.65
- CELC N/A
- 52 Week Low
- INDB $52.15
- CELC $7.58
- 52 Week High
- INDB $77.23
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- INDB 48.09
- CELC 73.52
- Support Level
- INDB $66.63
- CELC $64.61
- Resistance Level
- INDB $69.68
- CELC $80.13
- Average True Range (ATR)
- INDB 2.13
- CELC 4.87
- MACD
- INDB 0.05
- CELC 2.54
- Stochastic Oscillator
- INDB 66.90
- CELC 82.13
About INDB Independent Bank Corp.
Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.